Salarius Pharmaceuticals amends merger terms, adjusts preferred stock conversion
NeutralFinancial Markets

Salarius Pharmaceuticals has announced amendments to its merger terms, specifically adjusting the conversion of preferred stock. This change is significant as it reflects the company's ongoing efforts to optimize its financial structure and enhance shareholder value. Such adjustments can impact investor confidence and the overall market perception of the company.
— Curated by the World Pulse Now AI Editorial System